{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:46:53Z","timestamp":1761666413415,"version":"build-2065373602"},"reference-count":80,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jogc.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Obstetrics and Gynaecology Canada"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jogc.2020.10.008","type":"journal-article","created":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T19:46:53Z","timestamp":1609184813000},"page":"106-123.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Directive clinique no 408\u00a0: Prise en charge des maladies gestationnelles trophoblastiques"],"prefix":"10.1016","volume":"43","author":[{"given":"Lua","family":"Eiriksson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Dean","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Sebastianelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon","family":"Salvador","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn","family":"Comeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Hyun","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genevi\u00e8ve","family":"Bouchard-Fortier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ray","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Sauthier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jogc.2020.10.008_bib0001","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/PGP.0000000000000128","article-title":"Atypical placental site nodule (APSN) and association with malignant gestational trophoblastic disease; a clinicopathologic study of 21 cases","volume":"34","author":"Kaur","year":"2015","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0002","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/ng1740","article-title":"Mutations in NALP7 cause recurrent hydatidiform moles and reproductive wastage in humans","volume":"38","author":"Murdoch","year":"2006","journal-title":"Nat Gen"},{"key":"10.1016\/j.jogc.2020.10.008_bib0003","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ajhg.2011.08.002","article-title":"Mutations causing familial biparental hydatidiform mole implicate C6orf221 as a possible regulator of genomic imprinting in the human oocyte","volume":"89","author":"Parry","year":"2011","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jogc.2020.10.008_bib0004","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/s41379-018-0031-9","article-title":"The genetics of recurrent hydatidiform moles: new insights and lessons from a comprehensive analysis of 113 patients","volume":"31","author":"Nguyen","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0005","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.ajhg.2018.10.007","article-title":"Causative mutations and mechanisms of androgenetic hydatidiform moles","volume":"103","author":"Nguyen","year":"2018","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jogc.2020.10.008_bib0006","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1097\/PAS.0000000000000937","article-title":"Choriocarcinoma in women: analysis of a case series with genotyping","volume":"41","author":"Savage","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0007","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000486639","article-title":"Non-gestational choriocarcinoma with widespread metastases presenting with type 1 respiratory failure in a 39-year old female: case report and review of the literature","volume":"11","author":"Stockton","year":"2018","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0008","first-page":"285","article-title":"Differences in total human chorionic gonadotropin immunoassay analytical specificity and ability to measure human chorionic gonadotropin in gestational trophoblastic disease and germ cell tumors","volume":"55","author":"Harvey","year":"2010","journal-title":"J Reprod Med"},{"key":"10.1016\/j.jogc.2020.10.008_bib0009","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S1470-2045(03)01245-2","article-title":"Epidemiology and aetiology of gestational trophoblastic diseases","volume":"4","author":"Altieri","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ygyno.2016.07.117","article-title":"Effect of race\/ethnicity on risk of complete and partial molar pregnancy after adjustment for age","volume":"143","author":"Melamed","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"2 Pt 1","key":"10.1016\/j.jogc.2020.10.008_bib0011","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/AOG.0b013e3181802186","article-title":"Maternal age-related rates of gestational trophoblastic disease","volume":"112","author":"Altman","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0012","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1471-0528.2002.t01-1-01037.x","article-title":"Risk of partial and complete hydatidiform molar pregnancy in relation to maternal age","volume":"109","author":"Sebire","year":"2002","journal-title":"BJOG"},{"key":"10.1016\/j.jogc.2020.10.008_bib0013","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/01.AOG.0000174583.51617.25","article-title":"Postevacuation hCG levels and risk of gestational trophoblastic neoplasia in women with complete molar pregnancy","volume":"106","author":"Wolfberg","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0014","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/gyno.1993.1028","article-title":"Development of postmolar trophoblastic disease after partial molar pregnancy","volume":"48","author":"Goto","year":"1993","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0140-6736(00)02432-6","article-title":"Choriocarcinoma and partial hydatidiform moles","volume":"356","author":"Seckl","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jogc.2020.10.008_bib0016","first-page":"764","article-title":"Persistent gestational trophoblastic neoplasia after partial hydatidiform mole incidence and outcome","volume":"51","author":"Hancock","year":"2006","journal-title":"J Reprod Med"},{"key":"10.1016\/j.jogc.2020.10.008_bib0017","first-page":"254","article-title":"Complete hydatidiform mole in women aged 40 to 49 years","volume":"57","author":"Elias","year":"2012","journal-title":"J Reprod Med"},{"key":"10.1016\/j.jogc.2020.10.008_bib0018","first-page":"208","article-title":"Management of molar pregnancy","volume":"26","author":"Goldstein","year":"1981","journal-title":"J Reprod Med"},{"key":"10.1016\/j.jogc.2020.10.008_bib0019","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1093\/oxfordjournals.aje.a114337","article-title":"Choriocarcinoma incidence in the United States","volume":"123","author":"Brinton","year":"1986","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0020","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00003081-200309000-00006","article-title":"Gestational trophoblastic disease epidemiology and trends","volume":"46","author":"Smith","year":"2003","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0021","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1148\/rg.2017160140","article-title":"Gestational trophoblastic disease: clinical and imaging features","volume":"37","author":"Shaaban","year":"2017","journal-title":"Radiographics"},{"key":"10.1016\/j.jogc.2020.10.008_bib0022","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(04)16898-0","article-title":"Routine terminations of pregnancy \u2013 should we screen for gestational trophoblastic neoplasia?","volume":"364","author":"Seckl","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jogc.2020.10.008_bib0023","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.crad.2005.12.003","article-title":"Radiology of gestational trophoblastic neoplasia","volume":"61","author":"Allen","year":"2006","journal-title":"Clin Radiol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0024","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1006\/gyno.1998.5088","article-title":"Clinical outcome of micrometastases in the lung in stage IA persistent gestational trophoblastic disease","volume":"70","author":"Ngan","year":"1998","journal-title":"Gynecol Oncol"},{"issue":"3Pt1","key":"10.1016\/j.jogc.2020.10.008_bib0025","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1006\/gyno.2000.5839","article-title":"Gestational trophoblastic disease: a study of mode of evacuation and subsequent need for treatment with chemotherapy","volume":"78","author":"Tidy","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0026","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12885-018-5168-x","article-title":"Total hysterectomy versus uterine evacuation for preventing post-molar gestational trophoblastic neoplasia in patients who are at least 40 years old: a systematic review and meta-analysis","volume":"19","author":"Zhao","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jogc.2020.10.008_bib0027","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3109\/01443610903521882","article-title":"Internal iliac artery embolisation in the treatment of uncontrolled haemorrhage associated with placenta accreta and partial hydatidiform mole","volume":"30","author":"Unsal","year":"2010","journal-title":"J Obstet Gynaecol"},{"issue":"2 Pt 2","key":"10.1016\/j.jogc.2020.10.008_bib0028","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/AOG.0b013e318193bff3","article-title":"Balloon tamponade of hemorrhage after uterine curettage for gestational trophoblastic disease","volume":"113","author":"Kolomeyevskaya","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0029","article-title":"Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia","volume":"9","author":"Wang","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jogc.2020.10.008_bib0030","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/1097-0142(19860801)58:3<624::AID-CNCR2820580305>3.0.CO;2-6","article-title":"Prophylactic chemotherapy for hydatidiform mole five to 15 years follow-up","volume":"58","author":"Kashimura","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/j.jogc.2020.10.008_bib0031","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/00006250-198605000-00017","article-title":"Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole","volume":"67","author":"Kim","year":"1986","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0032","first-page":"110","article-title":"Prophylactic actinomycin D for high-risk complete hydatidiform mole","volume":"46","author":"Limpongsanurak","year":"2001","journal-title":"J Reprod Med"},{"key":"10.1016\/j.jogc.2020.10.008_bib0033","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1471-0528.2007.01320.x","article-title":"Shortened duration of human chorionic gonadotropin surveillance following complete or partial hydatidiform mole: evidence for revised protocol of a UK regional trophoblastic disease unit","volume":"114","author":"Sebire","year":"2007","journal-title":"BJOG"},{"key":"10.1016\/j.jogc.2020.10.008_bib0034","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ygyno.2017.12.008","article-title":"What is the optimal duration of human chorionic gonadotropin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients","volume":"148","author":"Coyle","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0035","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/01.AOG.0000136099.21216.45","article-title":"Low risk of relapse after achieving undetectable hCG levels in women with complete molar pregnancy","volume":"104","author":"Wolfberg","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0036","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/01.AOG.0000227754.12848.4e","article-title":"Low risk of relapse after achieving undetectable hCG levels in women with partial molar pregnancy","volume":"108","author":"Wolfberg","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0037","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ygyno.2007.03.010","article-title":"Recurrent gestational trophoblastic disease after hCG normalization following hydatidiform mole in the Netherlands","volume":"106","author":"Kerkmeijer","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0038","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ygyno.2013.03.010","article-title":"Risk of gestational trophoblastic neoplasia after hCG normalisation according to hydatidiform mole type","volume":"130","author":"Schmitt","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0039","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ygyno.2015.09.012","article-title":"Gestational trophoblastic neoplasia after spontaneous human chorionic gonadotropin normalization following molar pregnancy evacuation","volume":"139","author":"Braga","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0040","first-page":"221","article-title":"The role of contraception in the development of postmolar gestational trophoblastic tumor","volume":"78","author":"Deicas","year":"1991","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0041","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1186\/s12885-017-3904-2","article-title":"A metastatic invasive mole arising from iatrogenic uterus perforation","volume":"17","author":"Shen","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jogc.2020.10.008_bib0042","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ygyno.2017.01.021","article-title":"Multiple pregnancies with complete mole and coexisting normal fetus in North and South America: a retrospective multicenter cohort and literature review","volume":"145","author":"Lin","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"Suppl1","key":"10.1016\/j.jogc.2020.10.008_bib0043","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0020-7292(03)90120-2","article-title":"Gestational trophoblastic neoplasia, FIGO 2000 staging and classification","volume":"83","author":"Ngan","year":"2003","journal-title":"Int J Gynaecol Obstet"},{"issue":"Suppl 6","key":"10.1016\/j.jogc.2020.10.008_bib0044","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/annonc\/mdt345","article-title":"Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Seckl","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0045","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0140-6736(11)61265-8","article-title":"Chemotherapy and human chorionic gonadotropin concentrations 6 months after uterine evacuation of molar pregnancy: a retrospective cohort study","volume":"379","author":"Agarwal","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jogc.2020.10.008_bib0046","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ygyno.2005.12.048","article-title":"Gestational trophoblastic diseases: 4. Presentation with persistent low positive human chorionic gonadotropin test results","volume":"102","author":"Cole","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0047","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ygyno.2005.12.045","article-title":"Gestational trophoblastic diseases: 2. Hyperglycosylated hCG as a reliable marker of active neoplasia","volume":"102","author":"Cole","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0048","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ygyno.2005.12.046","article-title":"Gestational trophoblastic diseases: 3. Human chorionic gonadotropin free beta-subunit a reliable marker of placental site trophoblastic tumors","volume":"102","author":"Cole","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0049","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(10)60280-2","article-title":"Gestational trophoblastic disease","volume":"376","author":"Seckl","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jogc.2020.10.008_bib0050","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJMc066500","article-title":"Normal production of human chorionic gonadotropin in menopause","volume":"356","author":"Cole","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jogc.2020.10.008_bib0051","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/IGC.0b013e3181a40cf2","article-title":"Normal production of human chorionic gonadotropin in perimenopausal and menopausal women and after oophorectomy","volume":"19","author":"Cole","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.jogc.2020.10.008_bib0052","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ygyno.2007.01.053","article-title":"Management and outcome of health women with persistently elevated beta-hCG","volume":"106","author":"Palmieri","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0053","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/bjc.2012.65","article-title":"Uterine artery pulsatility index: a predictor of methotrexate resistance in gestational trophoblastic neoplasia","volume":"106","author":"Agarwal","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jogc.2020.10.008_bib0054","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ygyno.2008.10.003","article-title":"Does chest CT matter in the staging of GTN?","volume":"112","author":"Darby","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0055","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ygyno.2015.01.530","article-title":"Brain metastases in gestational trophoblastic neoplasia: an update on incidence, management and outcome","volume":"137","author":"Savage","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0056","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijgo.2008.12.015","article-title":"Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia","volume":"105","year":"2009","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.jogc.2020.10.008_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2015.09.083","article-title":"Mortality rate of gestational trophoblastic neoplasia with a FIGO score of \u226513","volume":"214","author":"Bolze","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0058","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1200\/JCO.2010.30.4386","article-title":"Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblasticneoplasia: a Gynecologic Oncology Group study","volume":"29","author":"Osborne","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0059","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ygyno.2010.02.029","article-title":"Weekly methotrexate (50 mg\/m2) without dose escalation as a primary regimen for low-risk gestational trophoblastic neoplasia","volume":"117","author":"Kang","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0060","unstructured":"Schink J, Gynecologic Oncology Group. Methotrexate or dactinomycin in treating patients with low-risk gestational trophoblastic neoplasia. (GOG 0275) Accessible au www.clinicaltrials.gov\/ct2\/show\/NCT01535053. Consult\u00e9 le 11 septembre 2018."},{"issue":"6","key":"10.1016\/j.jogc.2020.10.008_bib0061","article-title":"First-line chemotherapy in low-risk gestational trophoblastic neoplasia","author":"Lawrie","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jogc.2020.10.008_bib0062","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ygyno.2018.05.030","article-title":"First-line hysterectomy for women with low-risk, non-metastatic gestational trophoblastic neoplasia no longer wishing to conceive","volume":"150","author":"Bolze","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0063","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/AOG.0000000000001554","article-title":"Second curettage for low-risk nonmetastatic gestational trophoblastic neoplasia","volume":"128","author":"Osborne","year":"2016","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0064","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ygyno.2012.03.003","article-title":"Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia","volume":"125","author":"Lybol","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0065","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/sj.bjc.6605529","article-title":"The management and outcome of women with post-hydatidiform mole \u2018low-risk\u2019 gestational trophoblastic neoplasia, but hCG levels in excess of 100 000 IU\/L\u02c9\u00b9","volume":"102","author":"McGrath","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jogc.2020.10.008_bib0066","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1038\/bjc.2013.123","article-title":"Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements","volume":"108","author":"You","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jogc.2020.10.008_bib0067","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijgo.2011.04.017","article-title":"Etoposide, cisplatin-etoposide, methotrexate, actinomycin-D as primary treatment for management of very-high-risk gestational trophoblastic neoplasia","volume":"115","author":"Cyriac","year":"2011","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.jogc.2020.10.008_bib0068","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/ijgc-00009577-200301000-00018","article-title":"Transcatheter angiographic embolization for the control of massive pelvic hemorrhage due to gestational trophoblastic disease: a case series and review of the literature","volume":"13","author":"Moodley","year":"2003","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.jogc.2020.10.008_bib0069","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1200\/JCO.2012.43.1817","article-title":"EMA\/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis","volume":"31","author":"Alfrangis","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0070","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ygyno.2009.10.056","article-title":"Placental site trophoblastic tumor: lymphatic spread and possible target markers","volume":"116","author":"Lan","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0071","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0140-6736(09)60618-8","article-title":"Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study","volume":"374","author":"Schmid","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jogc.2020.10.008_bib0072","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/sj.bjc.6602899","article-title":"Residual lung lesions after completion of chemotherapy for gestational trophoblastic neoplasia: should we operate?","volume":"94","author":"Powles","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jogc.2020.10.008_bib0073","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1200\/JCO.2002.07.166","article-title":"Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000","volume":"20","author":"McNeish","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0074","first-page":"248","article-title":"Effect of early pregnancy following chemotherapy on disease relapse and fetal outcome in women treated for gestational trophoblastic neoplasia","volume":"59","author":"Williams","year":"2014","journal-title":"J Reprod Med"},{"key":"10.1016\/j.jogc.2020.10.008_bib0075","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ygyno.2008.10.027","article-title":"Maternal and perinatal outcomes of first pregnancy after chemotherapy for gestational trophoblastic neoplasia in Brazilian women","volume":"112","author":"Braga","year":"2009","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0076","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1200\/JCO.1996.14.10.2769","article-title":"Combination but not single agent methotrexate chemotherapy for gestational trophoblastic tumours increases the incidence of second tumours","volume":"14","author":"Rustin","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jogc.2020.10.008_bib0077","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00259-012-2324-4","article-title":"Role of 18F-FDG PET in the management of gestational trophoblastic neoplasia","volume":"40","author":"Mapelli","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jogc.2020.10.008_bib0078","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1016\/S0140-6736(17)32894-5","article-title":"Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia","volume":"390","author":"Ghorani","year":"2017","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.jogc.2020.10.008_bib0079","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ijgo.12615","article-title":"Update on the diagnosis and management of gestational trophoblastic disease","volume":"143","author":"Ngan","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"issue":"9 Suppl 3","key":"10.1016\/j.jogc.2020.10.008_bib0080","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1097\/IGC.0000000000000294","article-title":"Trophoblastic disease review for diagnosis and management: a joint report from the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup","volume":"24","author":"Mangili","year":"2014","journal-title":"Int J Gynecol Cancer"}],"container-title":["Journal of Obstetrics and Gynaecology Canada"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S170121632030832X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S170121632030832X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:38:24Z","timestamp":1761665904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S170121632030832X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S170121632030832X"],"URL":"https:\/\/doi.org\/10.1016\/j.jogc.2020.10.008","relation":{},"ISSN":["1701-2163"],"issn-type":[{"type":"print","value":"1701-2163"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Directive clinique no 408\u00a0: Prise en charge des maladies gestationnelles trophoblastiques","name":"articletitle","label":"Article Title"},{"value":"Journal of Obstetrics and Gynaecology Canada","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jogc.2020.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jogc.2020.03.001","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Society of Obstetricians and Gynaecologists of Canada\/La Soci\u00e9t\u00e9 des obst\u00e9triciens et gyn\u00e9cologues du Canada. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}